809MO Efficacy and safety results from the phase II study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma
Yufang Song(Lanzhou Institute of Husbandry and Pharmaceutical Sciences), Jiahui Zhu(Guangxi University), Songlin Hou(North Sichuan Medical University), Kaixin Zhou(Henan Cancer Hospital), Z. Wang(Shanghai Medical Information Center), Qing Lü(Shanghai Medical Information Center), Ning Lin(Nanning Normal University), Fei Li(University of Wisconsin System), Wei Meng(Shanghai Medical Information Center), Wei Tian(Ministry of Agriculture and Rural Affairs), Y. Zhang(Shandong University), Tienan Yi(Xiangyang Central Hospital), Wan Yang(China Medical University), Xinyu Liu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 1
Related Papers
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
|Journal of Clinical Oncology|2022|306
Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma
|Annals of Oncology|2013|126
Ascorbic Acid Sensitizes Colorectal Carcinoma to the Cytotoxicity of Arsenic Trioxide via Promoting Reactive Oxygen Species-Dependent Apoptosis and Pyroptosis
|Frontiers in Pharmacology|2020|51
Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivors
|EBioMedicine|2024|40
Pitolisant alleviates brain network dysfunction and cognitive deficits in a mouse model of Alzheimer’s disease
|Translational Psychiatry|2025|7